Focus Partners Advisor Solutions LLC Invests $518,000 in DexCom, Inc. $DXCM

Focus Partners Advisor Solutions LLC bought a new position in DexCom, Inc. (NASDAQ:DXCM) during the second quarter, Holdings Channel reports. The firm bought 7,688 shares of the medical device company’s stock, valued at approximately $518,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DXCM. Reflection Asset Management purchased a new position in DexCom during the 4th quarter valued at approximately $25,000. Ascentis Independent Advisors purchased a new stake in shares of DexCom during the 1st quarter worth approximately $25,000. MCF Advisors LLC purchased a new stake in shares of DexCom during the 4th quarter worth approximately $32,000. Wellington Grp LLC boosted its position in shares of DexCom by 778.7% during the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 475 shares during the last quarter. Finally, DV Equities LLC bought a new position in shares of DexCom during the 4th quarter valued at approximately $36,000. 97.75% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently weighed in on DXCM. Royal Bank Of Canada boosted their price target on shares of DexCom from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. UBS Group set a $96.00 price objective on shares of DexCom and gave the company a “buy” rating in a research report on Tuesday, July 28th. Truist Financial set a $93.00 price objective on shares of DexCom and gave the stock a “buy” rating in a research note on Friday, July 31st. Benchmark boosted their target price on shares of DexCom from $77.00 to $82.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of DexCom in a research report on Tuesday, June 23rd. They set a “buy” rating and a $86.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and a consensus target price of $88.71.

Insider Activity

In related news, Director Mark G. Foletta sold 2,000 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $85.32, for a total transaction of $170,640.00. Following the transaction, the director directly owned 48,852 shares in the company, valued at approximately $4,168,052.64. This represents a 3.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,911 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $74.13, for a total transaction of $364,052.43. Following the transaction, the executive vice president owned 95,450 shares in the company, valued at $7,075,708.50. The trade was a 4.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 99,794 shares of company stock worth $7,373,321. Insiders own 0.28% of the company’s stock.

DexCom Stock Performance

NASDAQ DXCM opened at $89.60 on Wednesday. The business’s 50 day moving average price is $76.55 and its 200-day moving average price is $70.56. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $91.96. The company has a market cap of $33.81 billion, a P/E ratio of 35.42, a P/E/G ratio of 1.51 and a beta of 1.41. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. The company had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.DexCom’s revenue was up 13.1% on a year-over-year basis. During the same period last year, the company earned $0.48 earnings per share. Sell-side analysts predict that DexCom, Inc. will post 2.64 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.